Erin Boyer

Human Resources Officer en UNIQURE N.V. .

Health Technology

Consumer Services

Perfil

Erin Boyer is currently the Chief People & Culture Officer at uniQure NV since 2022.
Previously, she worked as the Head-Global Talent Strategy & Planning at Alnylam Pharmaceuticals, Inc., Chief People & Culture Officer at Epizyme, Inc., and Vice President-Human Resources at Obsidian Therapeutics, Inc. Ms. Boyer completed her undergraduate degree at Macalester College.

Cargos activos de Erin Boyer

Empresas	Cargo	Inicio
UNIQURE N.V.	Human Resources Officer	01/04/2022

Todos los cargos activos de Erin Boyer

Antiguos cargos conocidos de Erin Boyer.

Empresas	Cargo	Fin
Obsidian Therapeutics, Inc. Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.	Human Resources Officer	-
ALNYLAM PHARMACEUTICALS, INC.	Corporate Officer/Principal	-
EPIZYME, INC.	Human Resources Officer	-

Ver el detalle de la experiencia de Erin Boyer.

Formación de Erin Boyer.

Macalester College

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Erin Boyer.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
ALNYLAM PHARMACEUTICALS, INC.	Health Technology
UNIQURE N.V.	Health Technology

Empresas privadas	2
Epizyme, Inc. Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.	Health Technology
Obsidian Therapeutics, Inc. Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA.	Health Technology